1.
Open Forum Infect Dis
; 11(8): ofae436, 2024 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-39139581
RESUMO
We report the experience of bictegravir/emtricitabine/tenofovir alafenamide for nonoccupational postexposure prophylaxis in sexual assault cases. Between June 2021 and October 2023, 39 individuals completed the 28-day follow-up; 41% experienced some side effects, and 1 person discontinued the drug because of a rash. No individuals seroconverted to HIV during the follow-up period.